90% of the JNJ posts are complete garbage by morons. For those interested in the facts, two issues loom: (1) Are the new growth forecasts realistic -ie- that JNJ will show decent organic growth in the second half? (2) Will the board realize that a break-up into three parts is the best way to go? If so, we are looking at $80. If the answer is no to both of the above, JNJ will continue to be in the backwater as an investment.
The company is already divided into three business units. I doubt it truly break up in separate companies. There may be some type of high level reorgnaization with increased oversight. Clearly the current sturcture has not worked well. The McNeil mess is still a mess. Be thankfull most of the trash has been tossed out. There was definaltely to high a relinace on internal metrics that can be easily manipulated to make everything look good. The pharma side has the best pipeline they have had in years.